Connect to other sites within the UBM Medica Network
GLP-1 Receptor Agonists Go Head-to-Head
This short slide show summarizes results of 8 phase III clinical trials, revealing favorable class efficacy and also differences that should be considered before treatment selection.
SGLT2 Inhibitors and Fracture Risk: A Review of What We Know
It's probably too early to pass judgment but data from clinical trials point to decreased bone mineral density and increased treatment-emergent fractures in patients taking the new antidiabetes drugs.
Have You Heard This (Week's) News?
Microbes in the gut affect metabolic pathways involved in the pathogenesis of obesity, insulin resistance, and diabetes. Antibiotics can alter gut microbiota.
Aflibercept (Eylea, Regeneron Pharmaceuticals), a second ophthalmic vascular endothelial growth factor inhibitor, has received FDA approval for the treatment of diabetic retinopathy.
Poor GLP-1 Response Seen Before Type 2 Diabetes Develops
A Danish study found reduced endogenous levels of glucagon-like peptide-1 in persons with prediabetes. Perhaps the incretin system defect comes first.
Do You Speak DPP-4I?
There are 10 FDA-approved DPP-4 inhibitors--single agents and combination products. Do you speak their language? Find out with these 5 questions.
Diabetes Quizlet: 3 Quick Questions
Spot check your memory for these disease details.
By clicking Accept, you agree to become a member of the UBM Medica Community.